Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Vertex Pharmaceuticals
Sort By
Newest First
Sign in
1 / 1
1 / 1
Collaboration
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
Vertex
PR-M04-21-024
Apr 22, 2021
Gene Editing
Vertex Announces New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies
Vertex
PR-M06-20-NI-017
Jun 12, 2020
Cell and Gene Therapy
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
Vertex
PR-M11-19-NI-023
Nov 20, 2019
Agreement
Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)
Vertex
PR-M09-19-NI-041
Sep 16, 2019
M&A
Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes
Vertex
PR-M09-19-NI-008
Sep 04, 2019
Leadership
Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman and Dr. Reshma Kewalramani Appointed as New CEO
Vertex
PR-M07-19-NI-076
Jul 29, 2019
FDA Approval
FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease
Vertex
PR-M08-18-NI-075
Aug 20, 2018
Research
BNBuilders Completes Construction on Vertex Pharmaceuticals Research Center in San Diego
BNBuilders
PR-M06-18-NI-082
Jun 26, 2018
